SUMATRIPTAN — 50 mg / 100 mg tablets (and other formulations)
📦 Product Snapshot
Use our inquiry form to request official leaflet links, verify common strengths, and ask general authenticity/packaging questions. We do not provide medical advice.
International visitors: our informational support and inquiry form are available to users in the United States, United Kingdom, and Australia.
🧠 Overview
Sumatriptan is a selective serotonin 5‑HT1B/1D receptor agonist, belonging to the triptan class of medications. It was the first triptan approved for the acute treatment of migraine and remains a cornerstone of migraine therapy. Sumatriptan is also FDA‑approved via subcutaneous injection for acute cluster headache, offering rapid relief for this severe condition.
Mechanism of action: Migraine pain is associated with dilatation of cranial blood vessels and release of inflammatory mediators from trigeminal nerves. Sumatriptan activates 5‑HT1B receptors on cranial arteries, causing vasoconstriction, and 5‑HT1D receptors on trigeminal nerve terminals, inhibiting the release of calcitonin gene‑related peptide and other pro‑inflammatory peptides. This dual action relieves pain and associated symptoms like nausea, photophobia, and phonophobia.
Pharmacokinetics and formulations: Oral sumatriptan has low and variable bioavailability (approximately 15%) due to presystemic metabolism and incomplete absorption. The maximum concentration after a 100 mg oral dose is 51 ng/mL, reached in 2‑2.5 hours. Subcutaneous injection offers near‑complete bioavailability (96%), with peak levels achieved in 12 minutes, making it the most effective formulation for rapid relief. Nasal spray and suppositories provide alternative routes for patients with nausea or difficulty swallowing.
Critical safety context: Sumatriptan causes vasoconstriction and is absolutely contraindicated in patients with coronary artery disease, history of myocardial infarction, stroke, uncontrolled hypertension, or hemiplegic/basilar migraine. Rare but serious cardiac events, including myocardial infarction and ventricular arrhythmias, have been reported even in patients without known cardiac disease. A cardiovascular evaluation is recommended for triptan‑naive patients with multiple risk factors before treatment.
🏷️ Strengths & Brand Examples
- Oral tablets: 25 mg, 50 mg, 100 mg (as succinate salt).
- Subcutaneous injection: 3 mg/0.5 mL, 4 mg/0.5 mL, 6 mg/0.5 mL prefilled syringes or pens.
- Nasal spray: 5 mg, 10 mg, 20 mg per actuation; also 11 mg nasal powder.
- Rectal suppositories: 12.5 mg, 25 mg (available in some markets).
- Combination: Sumatriptan 85 mg / naproxen sodium 500 mg (for migraine).
- Imitrex® (oral tablets, nasal spray, injection — US).
- Imigran® (oral tablets, nasal spray, injection — UK, Europe).
- Tosymra® (nasal spray 10 mg — US).
- Suminat® 25 mg / 50 mg / 100 mg tablets (Sun Pharma).
- Migranil® 50 mg tablets (Cipla).
- Sutrip® 50 mg film‑coated tablets (Rhydburg Pharmaceuticals).
- Sumitrex® (Abbott).
- Generic sumatriptan available from multiple manufacturers (Zydus, Alkem, Intas).
⚠️ Safety, Side Effects & Monitoring
- Paresthesia (tingling), warm/cold sensations.
- Chest pain, tightness, pressure, or heaviness (usually non‑cardiac, but evaluate if high risk).
- Neck/throat/jaw pain or pressure.
- Dizziness, vertigo, malaise, fatigue.
- Injection site reactions (pain, stinging, redness, swelling, bruising).
- Nasal spray: dysgeusia (bad taste), throat irritation, burning sensation.
- Nausea, vomiting (when not part of migraine).
- Flushing, weakness, drowsiness.
• Cerebrovascular events: Contraindicated in history of stroke or TIA. Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred, sometimes fatal. Exclude other neurological conditions before treating.
• Arrhythmias: Life‑threatening ventricular tachycardia/fibrillation reported. Discontinue if occurs.
• Other vasospasm: Peripheral vascular ischemia, gastrointestinal ischemia/infarction, Raynaud‘s syndrome. Discontinue if symptoms occur.
• Serotonin syndrome: Risk with SSRIs, SNRIs, TCAs, MAOIs. Symptoms include agitation, hallucinations, tachycardia, hyperthermia, hyperreflexia, incoordination, nausea/vomiting/diarrhea. Onset usually within minutes to hours. Discontinue sumatriptan if occurs.
• Medication overuse headache: Using triptans ≥10 days/month may worsen headache frequency. Detoxification may be needed.
• Hypertension: Contraindicated in uncontrolled hypertension. Can cause hypertensive crisis even in patients with normal BP.
• Seizures: Use with caution in epilepsy or lowered seizure threshold.
• Hypersensitivity: Angioedema, anaphylaxis reported.
• Severe hepatic impairment: Contraindicated (oral bioavailability markedly increased).
- Ischemic coronary artery disease (angina, history of MI, documented silent ischemia).
- Coronary artery vasospasm (Prinzmetal‘s angina).
- Wolff‑Parkinson‑White syndrome or other cardiac accessory conduction pathway disorders.
- History of stroke, transient ischemic attack (TIA).
- Hemiplegic or basilar migraine.
- Peripheral vascular disease.
- Ischemic bowel disease.
- Uncontrolled hypertension.
- Recent use (within 24 hours) of another 5‑HT1 agonist (another triptan) or ergotamine‑containing medication.
- Concurrent or recent (past 2 weeks) use of monoamine oxidase‑A inhibitor.
- Hypersensitivity to sumatriptan (angioedema, anaphylaxis).
- Severe hepatic impairment.
- Ergotamine derivatives (ergotamine, dihydroergotamine, methysergide) and other triptans: Additive vasospastic effects. Avoid within 24 hours of sumatriptan.
- MAO‑A inhibitors (phenelzine, tranylcypromine, moclobemide, linezolid): Contraindicated; increase sumatriptan exposure up to 7‑fold. Allow 2‑week washout.
- SSRIs/SNRIs (citalopram, fluoxetine, paroxetine, sertraline, venlafaxine): Serotonin syndrome risk. Monitor for symptoms.
- MAO‑B inhibitors (selegiline, rasagiline): No significant interaction, but caution advised.
- Alcohol: No pharmacokinetic interaction, but may worsen dizziness or sedation.
Oral: 25 mg, 50 mg, or 100 mg single dose. May repeat once after ≥2 hours if some response. Max 200 mg/24h. 50 mg and 100 mg may offer greater efficacy than 25 mg.
Subcutaneous: 1‑6 mg single dose. May repeat once after ≥1 hour. Max 12 mg/24h. For cluster headache: 6 mg SC at onset.
Nasal spray: 5‑20 mg single dose. May repeat once after ≥2 hours. Max 40 mg/24h.
Rectal: 12.5‑25 mg single dose. May repeat once after ≥2 hours.
Hepatic impairment: Mild‑moderate: max oral dose 50 mg/day. Severe: contraindicated.
Renal impairment: No dose adjustment needed.
Pregnancy: Limited data; based on animal studies, may cause fetal harm. Use only if clearly needed.
Breastfeeding: Excreted in milk. Avoid breastfeeding for 12 hours after dose; discard expressed milk during this period. Some women report temporary breast/nipple pain after use, resolving in 3‑12 hours.
Pediatric (<18 years): Safety not established for migraine (off‑label use in adolescents). Contraindicated in <18 for cluster headache.
Geriatric (>65 years): Limited experience; assess cardiac risk and use lower end of dosing range.